Trial Profile

Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Hydroxycarbamide
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Focus Therapeutic Use
Acronyms DALIAH

12 Dec 2023 Results(n=203 patients) comparing the efficacy and safety of HU vs low-dose IFN in patients with MPN over five years, presented at the 65th American Society of Hematology Annual Meeting and Exposition
13 Dec 2022 Results (n=179) assessing quality of life and symptom burden of patients with MPN , presented at the 64th American Society of Hematology Annual Meeting and Exposition
19 Apr 2022 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com